SCHEMBL737347

SCHEMBL737347

COc1cc(CO)c(Cl)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
CYP1A2 P05177 1/20 0.43
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.39
APLNR P35414 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16956666 0.82 ALDH1A1 (0.42) PDE4APDE4BPDE4CPDE4DCYP1A2
SCHEMBL8818739 0.82 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DCYP1A2
SCHEMBL10044442 0.82 CYP1A2 (0.44) CYP1A2ALDH1A1KDM4EHSD17B10APLNR
SCHEMBL205231 0.82 PDE4A (0.52) PDE4APDE4BPDE4CPDE4DCYP1A2
SCHEMBL14236162 0.79 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DALDH1A1
SCHEMBL28290894 0.79 CYP1A2 (0.46) CYP1A2ALDH1A1KDM4EHSD17B10APLNR
SCHEMBL3326056 0.79 HSD17B10 (0.61) ALDH1A1KDM4EHSD17B10GAAMAPT
SCHEMBL15883267 0.79 ALDH1A1 (0.53) CYP1A2ALDH1A1KDM4EHSD17B10CA12
SCHEMBL643649 0.78 CYP1A2 (0.62) PDE4APDE4BPDE4CPDE4DCYP1A2
SCHEMBL18362599 0.78 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365196-B2 FGFR inhibitor and application thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2022-06-21 US disclosed
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2021-05-06 US disclosed
US-8138340-B2 Bicyclononene derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-03-20 US disclosed
EP-1786814-B1 BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2010-03-31 EP disclosed
US-20090306123-A1 Bicyclononene derivaties ACTELION PHARMACEUTICALS LTD. (CH) 2009-12-10 US disclosed
EP-1786814-A1 BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2007-05-23 EP disclosed
WO-2006021402-A1 BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD. (CH) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11365196-B2 FGFR inhibitor and application thereof FGFR1, FGFR4, FGFR2 PDE4A 3367/4885PDE4B 2841/4885PDE4C 3606/4885
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF FGFR1, FGFR4, FGFR2 PDE4A 2957/4885PDE4B 2473/4885PDE4C 3305/4885
US-20090306123-A1 Bicyclononene derivaties REN, ACE, CYP51A1 PDE4A 800/4885PDE4B 645/4885PDE4C 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.